Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Nazzareno Galiè et al.|Pharmacological Research|2022Cited by 146
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT studyArturo Cesaro, Raffaele Marfella, Felice Gragnano et al.|Frontiers in Cardiovascular Medicine|2022Cited by 87
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registryPasquale Paolisso, Carmine Pizzi, Luca Bergamaschi et al.|Diabetes Research and Clinical Practice|2023Cited by 77
Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB PathwayGiuseppe Esposito, Giovanni Sarnelli|Frontiers in Pharmacology|2016Cited by 45
Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent MannerGiovanni Sarnelli, Giuseppe Esposito|PLoS ONE|2016Cited by 45